Medical Pharmacology: Chapter 34 — Anti-Cancer Drugs Part II -- Module 4 — Immune Checkpoint Inhibitors, Hormonal Oncology, and CAR-T Cell Therapy: Extended Clinical Cases

Chapter 34 — Anti-Cancer Drugs Part II — Module 4 — Immune Checkpoint Inhibitors, Hormonal Oncology, and CAR-T Cell Therapy: Extended Clinical Cases

1. [CASE 1 — QUESTION 1] A 57-year-old man with metastatic melanoma begins combination immunotherapy with ipilimumab (a CTLA-4 inhibitor that acts during T-cell priming in lymph nodes) plus nivolumab (a PD-1 inhibitor that acts at the tumor in the effector phase). Before the first infusion, he asks the oncology team what to expect regarding side effects compared with single-agent therapy. Integrating the phase-of-action of each agent with its toxicity profile, what should the team anticipate and prepare for?

A) Fewer immune-related adverse events than single-agent therapy, because the two drugs neutralize each other's immune activation.
B) A higher rate and often earlier onset of immune-related adverse events than single-agent PD-1 blockade, because releasing the brake at both the priming and effector phases broadens T-cell activation, so the team should be ready to initiate corticosteroids promptly.
C) Toxicity confined strictly to the skin, because dual checkpoint blockade affects only dermal T cells.
D) Predictable myelosuppression at days 10 to 14, identical to cytotoxic chemotherapy.
E) No change in toxicity, because adding a second checkpoint inhibitor does not alter immune activation.

ANSWER: B

Rationale:

Blocking CTLA-4 broadens the pool of primed T cells in lymph nodes and blocking PD-1 restores effector activity at the tumor; combining the two amplifies T-cell activation at both phases. Because immune-related adverse events arise from that same activation, the combination produces more frequent and often earlier and more severe events, so the team must be prepared to start corticosteroids promptly.

Option A: Option A is incorrect because the agents act at complementary phases and do not neutralize each other; toxicity rises rather than falls.
Option C: Option C is incorrect because dual blockade causes multi-organ autoimmune toxicity, not skin-limited effects.
Option D: Option D is incorrect because checkpoint inhibitors cause immune-mediated, not predictable cytotoxic, myelosuppression.
Option E: Option E is incorrect because adding CTLA-4 blockade demonstrably increases immune activation and toxicity.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. Two weeks into combination ipilimumab-nivolumab therapy, he develops 8 watery stools per day above baseline with crampy abdominal pain. Stool studies including C. difficile testing are negative and infection has been excluded; this is grade 3 immune-mediated colitis. What is the most appropriate management?

A) Continue both agents at full dose and start loperamide as definitive therapy.
B) Begin oral vancomycin for presumed infectious colitis and continue both checkpoint inhibitors.
C) Start low-dose prednisone at 0.25 mg/kg/day and proceed with the next scheduled cycle of ipilimumab.
D) Permanently discontinue ipilimumab, start IV methylprednisolone 1-2 mg/kg/day, and add infliximab if there is no improvement within about 3 days.
E) Administer a single dose of infliximab without corticosteroids and rechallenge ipilimumab in one week.

ANSWER: D

Rationale:

Grade 3 immune colitis requires permanent discontinuation of the CTLA-4 agent (ipilimumab), prompt high-dose corticosteroids (methylprednisolone 1-2 mg/kg/day), and escalation to infliximab — the steroid-sparing agent of choice for colitis — if there is no improvement within roughly 72 hours.

Option A: Option A is incorrect because continuing the drugs and relying on an antimotility agent does not treat the immune inflammation and risks perforation.
Option B: Option B is incorrect because infection has been excluded, so antibiotics are not the treatment for immune colitis.
Option C: Option C is incorrect because grade 3 colitis requires high-dose, not subtherapeutic, corticosteroids, and ipilimumab should not be continued.
Option E: Option E is incorrect because infliximab is added to corticosteroids rather than used alone, and rechallenge with ipilimumab after grade 3 colitis is contraindicated.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. While on high-dose corticosteroids for his colitis, his transaminases rise to an AST of 290 U/L and ALT of 360 U/L (more than 5 times the upper limit of normal), consistent with concurrent grade 3 immune-mediated hepatitis; viral and obstructive causes are excluded. The transaminases continue to climb despite the steroids. What is the most appropriate next step?

A) Add mycophenolate mofetil and avoid infliximab, because anti-TNF therapy carries its own risk of hepatotoxicity in this setting; mycophenolate also provides immunosuppression for the refractory colitis.
B) Add infliximab, since it is the universal steroid-sparing agent for every immune-related adverse event.
C) Stop all corticosteroids because they are hepatotoxic and observe off therapy.
D) Administer tocilizumab as first-line treatment for the hepatitis.
E) Begin a somatostatin analog to reduce the hepatic inflammation.

ANSWER: A

Rationale:

For steroid-refractory immune hepatitis, mycophenolate mofetil is the steroid-sparing agent of choice, while infliximab is avoided because anti-TNF therapy can itself cause hepatotoxicity; mycophenolate additionally provides immunosuppression that addresses the concurrent refractory colitis.

Option B: Option B is incorrect because infliximab is contraindicated by the hepatitis.
Option C: Option C is incorrect because corticosteroids are first-line for immune hepatitis, not a class to abandon, and stopping all therapy leaves a worsening process untreated.
Option D: Option D is incorrect because tocilizumab is not the standard treatment for immune hepatitis.
Option E: Option E is incorrect because somatostatin analogs treat neuroendocrine tumors and have no role in immune hepatitis.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. Several weeks later, after his colitis and hepatitis have resolved, he presents to the emergency department with hypotension (BP 80/48 mmHg), vomiting, a sodium of 127 mEq/L, and a potassium of 5.7 mEq/L. Immune-mediated hypophysitis with secondary adrenal insufficiency precipitating an adrenal crisis is suspected. What is the most appropriate immediate action?

A) Withhold all steroids until a morning cortisol and ACTH level return the next day.
B) Administer levothyroxine first and defer glucocorticoids until thyroid studies return.
C) Give IV hydrocortisone (stress-dose, for example 100 mg) immediately, without waiting for confirmatory test results.
D) Increase the checkpoint inhibitor dose to restore adrenal output.
E) Start fludrocortisone alone, since mineralocorticoid replacement is sufficient.

ANSWER: C

Rationale:

Adrenal crisis is life-threatening; the immediate, life-saving action is stress-dose IV hydrocortisone given empirically without waiting for confirmatory testing. In a non-urgent presentation one would draw ACTH (adrenocorticotropic hormone) and cortisol first, but hemodynamic instability mandates treating immediately.

Option A: Option A is incorrect because delaying glucocorticoid to await testing in a crisis can be fatal.
Option B: Option B is incorrect and hazardous because giving levothyroxine before glucocorticoid replacement can worsen or precipitate adrenal crisis.
Option D: Option D is incorrect because raising the checkpoint inhibitor dose does not restore adrenal function and may worsen gland injury.
Option E: Option E is incorrect because glucocorticoid (hydrocortisone) replacement is the essential treatment; mineralocorticoid alone is inadequate in this crisis.

5. [CASE 2 — QUESTION 1] A 69-year-old woman with metastatic non-small-cell lung cancer is receiving single-agent pembrolizumab (a PD-1 inhibitor). After several cycles she develops progressive dyspnea and a dry cough; chest CT shows new diffuse bilateral ground-glass opacities, and her oxygen saturation is 87% on room air at rest, consistent with grade 3 immune-mediated pneumonitis. Which management plan is most appropriate?

A) Continue pembrolizumab, give empiric antibiotics alone, and withhold corticosteroids.
B) Start corticosteroids but resume pembrolizumab at the next cycle regardless of grade.
C) Observe without treatment, since pneumonitis resolves spontaneously even at grade 3.
D) Treat with tocilizumab as first-line therapy and continue pembrolizumab at full dose.
E) Evaluate to exclude infection (bronchoscopy with lavage when feasible), start corticosteroids 1-2 mg/kg/day, and permanently discontinue pembrolizumab given the grade 3 severity.

ANSWER: E

Rationale:

Immune pneumonitis requires exclusion of infection (bronchoscopy with lavage when feasible), corticosteroids at 1-2 mg/kg/day for grade 2 or higher, and permanent discontinuation of the checkpoint inhibitor for grade 3-4 disease, because high-grade pneumonitis can be fatal.

Option A: Option A is incorrect because withholding corticosteroids while continuing the drug ignores the immune etiology and the need to stop therapy.
Option B: Option B is incorrect because rechallenge is precluded by grade 3 severity.
Option C: Option C is incorrect because grade 3 pneumonitis is potentially life-threatening and mandates prompt corticosteroids and drug discontinuation.
Option D: Option D is incorrect because corticosteroids, not tocilizumab, are first-line, and the drug must be stopped.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. Before the pneumonitis developed, during an earlier cycle she had reported palpitations; at that time her TSH was 0.03 mIU/L (suppressed) with an elevated free T4 and a heart rate of 116 beats per minute, consistent with checkpoint inhibitor-induced thyroiditis in its hyperthyroid phase. How should that thyroid finding have been managed?

A) Treat symptoms with a beta-blocker, continue pembrolizumab, and monitor thyroid function, anticipating that the hyperthyroid phase is transient and commonly progresses to hypothyroidism within several weeks.
B) Start methimazole and refer for radioactive iodine ablation, as this represents Graves disease.
C) Begin levothyroxine immediately to correct the elevated free T4.
D) Start high-dose corticosteroids as first-line therapy and permanently discontinue pembrolizumab for the thyroid finding.
E) Discontinue pembrolizumab permanently and take no further action.

ANSWER: A

Rationale:

Checkpoint inhibitor thyroiditis typically begins with a transient hyperthyroid phase from release of preformed hormone as the gland is inflamed; management is symptomatic with a beta-blocker, the drug is continued, and the patient is monitored because the gland commonly becomes hypothyroid within weeks.

Option B: Option B is incorrect because this is destructive thyroiditis, not Graves disease; antithyroid drugs and radioactive iodine are not the treatment.
Option C: Option C is incorrect because levothyroxine treats hypothyroidism and would worsen the current hyperthyroid phase; it is started later if hypothyroidism develops.
Option D: Option D is incorrect because corticosteroids are not first-line for routine thyroiditis, which is self-limited, and discontinuation for the thyroid finding alone is unnecessary.
Option E: Option E is incorrect because symptomatic treatment and monitoring are required rather than no action.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. At the time of diagnosis, her oncologist reviewed molecular and immunohistochemical testing to estimate the likelihood of benefit from PD-1 blockade, including PD-L1 expression, tumor mutational burden (TMB, the number of mutations per megabase of tumor DNA), and microsatellite instability-high/mismatch-repair-deficient (MSI-H/dMMR) status. Which statement most precisely distinguishes these predictive biomarkers?

A) PD-L1 expression and TMB are identical measurements reported in different units.
B) MSI-H/dMMR status measures the percentage of tumor cells expressing PD-L1 protein on their surface.
C) MSI-H/dMMR reflects a defect in DNA mismatch repair that generates a high neoantigen load and predicts response to PD-1 blockade across tumor types, distinct from quantifying PD-L1 protein (immunohistochemistry) or counting total mutations as TMB.
D) TMB measures how strongly the PD-1 receptor is expressed on circulating T cells.
E) PD-L1 expression predicts response only in MSI-H tumors and is meaningless otherwise.

ANSWER: C

Rationale:

MSI-H/dMMR reflects loss of mismatch-repair function, producing many mutations and neoantigens that make the tumor more visible to T cells, and it predicts response to PD-1 blockade in a tissue-agnostic manner. This is mechanistically and methodologically distinct from PD-L1 immunohistochemistry (which quantifies ligand protein) and from TMB (which counts mutations per megabase).

Option A: Option A is incorrect because PD-L1 expression and TMB measure different things (ligand protein versus mutation count).
Option B: Option B is incorrect because MSI-H/dMMR is a DNA-repair status, not a measure of PD-L1 protein.
Option D: Option D is incorrect because TMB quantifies tumor mutations, not PD-1 receptor density on T cells.
Option E: Option E is incorrect because PD-L1 expression has predictive value in many non-MSI-H settings.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. Suppose that at the time pembrolizumab was first being considered, she had been taking chronic prednisone 30 mg/day for an unrelated inflammatory condition. Integrating the mechanism of checkpoint blockade with corticosteroid pharmacology, how should that baseline steroid use have been addressed before starting therapy?

A) The baseline steroid is irrelevant to checkpoint inhibitor efficacy and requires no change.
B) High-dose baseline corticosteroids can attenuate checkpoint inhibitor response by broadly suppressing the very T-cell activity the drug aims to unleash, so tapering to less than about 10 mg/day of prednisone equivalent before initiation is preferred when clinically feasible.
C) The baseline steroid should be increased to maximize checkpoint inhibitor efficacy.
D) The checkpoint inhibitor will fail completely in any patient on steroids, so it should never be offered.
E) Baseline steroids prevent all immune-related adverse events, so the high dose should be maintained throughout therapy as prophylaxis.

ANSWER: B

Rationale:

Checkpoint inhibitors restore T-cell activity, but high-dose systemic corticosteroids broadly suppress T cells and can blunt that response; retrospective data link baseline prednisone above roughly 10 mg/day to attenuated efficacy, so tapering below that threshold before initiation is preferred when clinically feasible.

Option A: Option A is incorrect because high-dose baseline steroids do affect efficacy.
Option C: Option C is incorrect because increasing steroids would further suppress the T-cell response.
Option D: Option D is incorrect because steroids attenuate but do not categorically abolish response, and therapy can still be appropriate after tapering.
Option E: Option E is incorrect because maintaining high-dose steroids as prophylaxis would undermine efficacy; immune-related adverse events are treated when they occur rather than blanket-prevented with high-dose steroids.

9. [CASE 3 — QUESTION 1] A 67-year-old man with newly diagnosed metastatic prostate cancer has a high tumor burden including extensive vertebral metastases. His oncologist plans to begin androgen deprivation therapy with leuprolide (a GnRH agonist). What intervention is required at initiation, and why?

A) No additional medication is needed, because leuprolide lowers testosterone within hours of the first dose.
B) Start finasteride to block dihydrotestosterone formation during the initial surge.
C) Begin an aromatase inhibitor to suppress the expected estrogen surge.
D) Co-prescribe a short course of an antiandrogen (for example, bicalutamide 50 mg daily for about 4 weeks), starting before and during leuprolide initiation, to prevent the testosterone flare from worsening disease and precipitating spinal cord compression.
E) Initiate lifelong corticosteroids before the first leuprolide dose.

ANSWER: D

Rationale:

Continuous GnRH receptor stimulation initially raises luteinizing hormone and testosterone (the flare) before downregulation lowers testosterone over one to two weeks; in a patient with vertebral metastases, the flare risks spinal cord compression. A short antiandrogen course (bicalutamide) given before and during initiation blocks the androgen receptor and covers the flare.

Option A: Option A is incorrect because testosterone initially rises rather than falling within hours.
Option B: Option B is incorrect because finasteride does not adequately block the androgen-receptor-mediated flare and is not the standard protection.
Option C: Option C is incorrect because the relevant surge is testosterone, not estrogen, and aromatase inhibitors are used in breast cancer.
Option E: Option E is incorrect because corticosteroids do not block the androgen receptor and are not used for flare protection.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. After an initial response, his disease progresses to castration-resistant prostate cancer and abiraterone (an inhibitor of CYP17A1, the enzyme that synthesizes androgens in the adrenal glands, testes, and tumor) is started. Which co-administration requirement and administration rule are correct for abiraterone?

A) Co-administer a strong CYP3A4 inducer and take abiraterone with a high-fat meal to maximize absorption.
B) Co-administer prednisone 5 mg twice daily to replace cortisol and suppress the ACTH-driven mineralocorticoid excess, and take abiraterone on an empty stomach because a high-fat meal can raise its exposure roughly 5-fold.
C) No corticosteroid is needed, and abiraterone should be taken with grapefruit juice to enhance bioavailability.
D) Co-administer fludrocortisone to add mineralocorticoid, and take abiraterone at bedtime with milk.
E) Co-administer levothyroxine to prevent hypothyroidism, and take abiraterone with the largest meal of the day.

ANSWER: B

Rationale:

CYP17A1 inhibition reduces cortisol synthesis, triggering compensatory ACTH (adrenocorticotropic hormone) elevation that drives accumulation of mineralocorticoid precursors causing hypertension, hypokalemia, and fluid retention; concurrent prednisone 5 mg twice daily replaces cortisol and suppresses ACTH. The standard formulation must be taken on an empty stomach because a high-fat meal raises exposure about 5-fold.

Option A: Option A is incorrect because an inducer would lower abiraterone levels and high-fat dosing is exactly what to avoid.
Option C: Option C is incorrect because prednisone is mandatory and grapefruit juice is not an appropriate way to alter dosing.
Option D: Option D is incorrect because the problem is mineralocorticoid excess, not deficiency, so fludrocortisone would worsen it.
Option E: Option E is incorrect because levothyroxine is unrelated and abiraterone must be taken fasting.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. At a routine visit several weeks into abiraterone therapy, his blood pressure is 162/98 mmHg and his serum potassium is 3.0 mEq/L; he feels well otherwise. Which interpretation and management plan is correct?

A) These findings are unrelated to abiraterone and require no change in therapy.
B) This indicates abiraterone underdosing; increase the dose and stop the prednisone.
C) This reflects cortisol excess; discontinue prednisone immediately.
D) Abiraterone has been converted to a mineralocorticoid antagonist; restrict dietary potassium.
E) This is mineralocorticoid excess from CYP17A1 inhibition (reduced cortisol drives compensatory ACTH and accumulation of mineralocorticoid precursors); confirm the patient is taking prednisone 5 mg twice daily, replete potassium, and add an antihypertensive as needed.

ANSWER: E

Rationale:

Inhibiting CYP17A1 lowers cortisol, which raises ACTH (adrenocorticotropic hormone) and drives accumulation of mineralocorticoid precursors, producing hypertension and hypokalemia. Management confirms adherence to prednisone 5 mg twice daily (which suppresses ACTH and replaces cortisol), repletes potassium, and adds an antihypertensive as needed.

Option A: Option A is incorrect because the derangement is directly caused by abiraterone's mechanism.
Option B: Option B is incorrect because the syndrome reflects expected pharmacology, not underdosing, and stopping prednisone would worsen it.
Option C: Option C is incorrect because the problem is reduced cortisol with mineralocorticoid excess, not cortisol excess; stopping prednisone would aggravate it.
Option D: Option D is incorrect because abiraterone causes mineralocorticoid excess, not antagonism, and potassium needs repletion rather than restriction.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. Later in his course, an additional androgen-receptor inhibitor is considered. His history now includes a seizure disorder, and he takes several medications metabolized by CYP3A4. Which androgen-receptor inhibitor is the best choice, and why?

A) Darolutamide, because its structurally distinct binding domain limits central nervous system penetration (so it does not lower the seizure threshold as enzalutamide can) and it is not a strong CYP inducer, giving a more favorable interaction profile in a patient with seizure history and polypharmacy.
B) Enzalutamide, because its central nervous system penetration is protective against seizures.
C) Enzalutamide, because a seizure history increases its anti-tumor efficacy.
D) Apalutamide, because it has the lowest reported rate of skin rash and hypothyroidism of the class.
E) Abiraterone without prednisone, since it has no central nervous system effects.

ANSWER: A

Rationale:

Darolutamide's distinct structure limits central nervous system penetration, so it does not lower the seizure threshold the way enzalutamide can, and it lacks strong CYP induction, producing a cleaner interaction profile; this makes it preferred in a patient with a seizure history and significant polypharmacy.

Option B: Option B is incorrect because greater central nervous system penetration raises, not lowers, seizure risk, and enzalutamide is the agent to avoid here.
Option C: Option C is incorrect because seizure history is a safety concern, not a driver of efficacy.
Option D: Option D is incorrect because apalutamide shares enzalutamide's seizure-threshold and CYP-induction concerns and actually carries notable rash and hypothyroidism risk.
Option E: Option E is incorrect because abiraterone requires mandatory concurrent prednisone, so giving it without prednisone is unsafe, and it is a different mechanistic class.

13. [CASE 4 — QUESTION 1] A 46-year-old premenopausal woman with ER-positive early breast cancer is started on adjuvant tamoxifen (a prodrug converted by CYP2D6, a hepatic enzyme, to its active metabolite endoxifen). She reports disruptive hot flashes and asks for medication to relieve them. Which choice is most appropriate, and why?

A) Paroxetine, because it enhances conversion of tamoxifen to its active metabolite.
B) Fluoxetine, because CYP2D6 inhibition does not affect tamoxifen activity.
C) Venlafaxine (or gabapentin or clonidine), because it relieves hot flashes without strongly inhibiting CYP2D6, preserving conversion of tamoxifen to active endoxifen.
D) Discontinue tamoxifen and switch to an aromatase inhibitor, since hot flashes contraindicate endocrine therapy.
E) Paroxetine combined with a CYP2D6 inducer to keep endoxifen levels neutral.

ANSWER: C

Rationale:

Tamoxifen requires CYP2D6 to form active endoxifen, so strong CYP2D6 inhibitors such as paroxetine and fluoxetine can reduce endoxifen and blunt efficacy; venlafaxine, desvenlafaxine, gabapentin, or clonidine relieve hot flashes without significant CYP2D6 inhibition and are preferred.

Option A: Option A is incorrect because paroxetine inhibits, rather than enhances, the CYP2D6-mediated activation of tamoxifen.
Option B: Option B is incorrect because CYP2D6 inhibition clearly reduces endoxifen, the basis for avoiding fluoxetine.
Option D: Option D is incorrect because hot flashes are managed pharmacologically and do not contraindicate endocrine therapy, and an aromatase inhibitor is ineffective in a premenopausal woman without ovarian suppression.
Option E: Option E is incorrect because combining an inhibitor with an inducer is unreliable and still risks reduced efficacy.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Years later she has gone through menopause and develops ER-positive metastatic disease; an aromatase inhibitor (letrozole) is selected. She asks how the drug works and why it is appropriate now but would not have been effective on its own when she was premenopausal. What is the correct explanation?

A) Aromatase inhibitors degrade the estrogen receptor directly, so they work in any hormonal state.
B) Aromatase inhibitors stimulate the ovaries to make more estrogen, which paradoxically slows the tumor.
C) Aromatase inhibitors block conversion of estrogen back into androgens, which is only relevant after menopause.
D) Aromatase inhibitors are effective only when the ovaries are actively producing large amounts of estrogen.
E) Aromatase inhibitors block aromatase (CYP19A1), reducing the peripheral conversion of androgens to estrogen in fat, adrenal, and breast tissue; this is the dominant estrogen source after menopause, whereas in a premenopausal woman ongoing ovarian estrogen production cannot be controlled by aromatase inhibition alone.

ANSWER: E

Rationale:

After menopause the ovaries no longer produce estrogen, and the dominant source becomes peripheral aromatization of androgens to estrogen in fat, adrenal, and breast tissue; blocking aromatase (CYP19A1) removes that supply. In a premenopausal woman, the ovaries still make large amounts of estrogen that aromatase inhibition cannot control, so the drugs are used only with ovarian suppression.

Option A: Option A is incorrect because aromatase inhibitors block estrogen synthesis rather than degrading the receptor (that is a SERD), and they are not effective in any hormonal state.
Option B: Option B is incorrect because aromatase inhibitors reduce estrogen rather than stimulating ovarian production.
Option C: Option C is incorrect because aromatase converts androgens to estrogen, not the reverse.
Option D: Option D is incorrect because it inverts the truth: active ovarian production is precisely the situation in which aromatase inhibitors fail to control estrogen.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. After an extended response to letrozole, her disease progresses, and a liquid biopsy (circulating tumor DNA) detects an ESR1 (estrogen receptor 1 gene) mutation. Integrating the mechanism of aromatase inhibitor resistance with the rationale for the next agent, which choice and reasoning are correct?

A) Re-treat with a higher dose of letrozole, because ESR1 mutations increase sensitivity to aromatase blockade.
B) Use a selective estrogen receptor degrader such as oral elacestrant, because ESR1 mutations cause ligand-independent receptor activation that aromatase inhibition cannot overcome, and elacestrant is specifically indicated for ESR1-mutant metastatic disease after prior endocrine therapy.
C) Add a CYP3A4 inducer to lower estrogen levels further.
D) Begin a GnRH agonist, since ovarian suppression overcomes ESR1-mediated resistance in postmenopausal women.
E) Switch to tamoxifen monotherapy, because ESR1-mutant receptors lose all estrogen responsiveness.

ANSWER: B

Rationale:

ESR1 mutations produce a constitutively active, ligand-independent estrogen receptor, so lowering estrogen with an aromatase inhibitor no longer controls signaling — the basis of acquired resistance. A selective estrogen receptor degrader that eliminates the receptor itself is the rational next step, and elacestrant is specifically indicated for ESR1-mutant metastatic disease after endocrine therapy.

Option A: Option A is incorrect because ESR1 mutation confers resistance to, not enhanced sensitivity to, aromatase blockade.
Option C: Option C is incorrect because the receptor is active independent of estrogen, so further lowering estrogen does not help, and a CYP3A4 inducer is not an endocrine strategy.
Option D: Option D is incorrect because the patient is postmenopausal, so ovarian suppression does not address the ESR1-driven, estrogen-independent signaling.
Option E: Option E is incorrect because tamoxifen, a partial agonist, is not the targeted choice for ligand-independent ESR1-mutant receptors.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. Reflecting on her earlier years on tamoxifen, the team reviews the long-term risks of the drug. Tamoxifen acts as an estrogen-receptor antagonist in breast tissue but as a partial agonist in other tissues. Which adverse-effect profile and monitoring approach correctly reflect this tissue-selective activity?

A) Tamoxifen lowers endometrial cancer risk and eliminates any thromboembolic risk, so no monitoring is needed.
B) Tamoxifen causes profound bone loss identical to aromatase inhibitors and requires routine DEXA but carries no uterine or clot risk.
C) Tamoxifen's only notable long-term risk is hepatotoxicity, monitored with periodic liver enzymes alone.
D) Because of partial estrogen-agonist activity in the endometrium, tamoxifen increases endometrial cancer risk approximately 2-fold and also raises venous thromboembolism risk, so patients should be counseled to report abnormal vaginal bleeding and undergo appropriate gynecologic evaluation.
E) Tamoxifen induces ovarian failure that protects against all estrogen-related cancers.

ANSWER: D

Rationale:

Tamoxifen's partial estrogen-agonist effect in the endometrium increases endometrial cancer risk roughly 2-fold, and it also raises venous thromboembolism risk; patients should be counseled to report abnormal vaginal bleeding and undergo appropriate gynecologic evaluation, with annual assessment.

Option A: Option A is incorrect because it inverts the truth: tamoxifen raises, not lowers, endometrial cancer risk and increases thromboembolic risk.
Option B: Option B is incorrect because the characteristic estrogen-agonist effect on bone tends to preserve bone density (unlike aromatase inhibitors), and uterine and clot risks are real.
Option C: Option C is incorrect because the dominant long-term concerns are endometrial cancer and thromboembolism, not isolated hepatotoxicity.
Option E: Option E is incorrect because tamoxifen does not induce protective ovarian failure and does not eliminate estrogen-related cancer risk.

17. [CASE 5 — QUESTION 1] A 34-year-old man with refractory diffuse large B-cell lymphoma is scheduled for CD19-directed CAR-T (chimeric antigen receptor T-cell) therapy. Before the engineered cells are infused, he receives lymphodepleting chemotherapy with fludarabine and cyclophosphamide. He asks why the chemotherapy is given and whether the design of the CAR-T product matters. Integrating the purpose of lymphodepletion with the role of the co-stimulatory domain, which statement is correct?

A) Lymphodepletion removes competing endogenous lymphocytes and creates cytokine space (including IL-7 and IL-15) that supports CAR-T expansion and persistence, while CD28-based constructs tend to drive faster, earlier expansion and often earlier cytokine release syndrome than 4-1BB-based constructs.
B) Lymphodepletion is given to suppress the CAR-T cells so they expand more slowly, and the co-stimulatory domain has no effect on the timing of cytokine release syndrome.
C) Lymphodepletion is unnecessary and is given only to treat the underlying cancer directly, and both constructs behave identically.
D) The 4-1BB domain causes the most rapid onset of cytokine release syndrome, and lymphodepletion exists to prevent CAR-T persistence.
E) Lymphodepletion eliminates the need to monitor for cytokine release syndrome regardless of construct.

ANSWER: A

Rationale:

Lymphodepleting chemotherapy removes competing endogenous lymphocytes and creates cytokine space (notably IL-7 and IL-15) that supports CAR-T expansion and persistence; the co-stimulatory domain shapes kinetics, with CD28-based constructs generally expanding faster and being associated with earlier cytokine release syndrome onset than 4-1BB-based constructs.

Option B: Option B is incorrect because lymphodepletion supports, rather than suppresses, CAR-T expansion, and the domain does influence cytokine release syndrome timing.
Option C: Option C is incorrect because lymphodepletion is integral to conditioning (not direct anticancer therapy) and the constructs are not identical.
Option D: Option D inverts the kinetics — CD28, not 4-1BB, is associated with earlier onset, and lymphodepletion promotes rather than prevents persistence.
Option E: Option E is incorrect because vigilant monitoring for cytokine release syndrome is always required after infusion.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. Four days after CAR-T infusion he develops a fever of 39.3 degrees Celsius and hypotension that responds to intravenous fluids; he requires low-flow supplemental oxygen. His neurological examination is normal, and infection is being evaluated concurrently. Which targeted treatment is most appropriate?

A) Dexamethasone alone, treating this as neurotoxicity.
B) No treatment, since fever after CAR-T never requires intervention.
C) Tocilizumab (an anti-IL-6-receptor antibody), because fever with fluid-responsive hypotension and a normal neurological examination fits cytokine release syndrome; corticosteroids are added for higher-grade or refractory disease.
D) A GnRH agonist to blunt the inflammatory surge.
E) Levothyroxine, to correct a presumed thyroid cause.

ANSWER: C

Rationale:

Fever with fluid-responsive hypotension and a normal neurological examination is the picture of cytokine release syndrome, the IL-6-driven syndrome, so the targeted treatment is tocilizumab, with corticosteroids added for higher-grade or refractory disease; the normal neurological exam argues against ICANS.

Option A: Option A is incorrect because there are no neurological findings to indicate ICANS, so steroid-first neurotoxicity treatment does not fit.
Option B: Option B is incorrect because cytokine release syndrome can be serious and this presentation requires treatment while infection is evaluated.
Option D: Option D is incorrect because GnRH agonists are prostate cancer therapies with no role in cytokine release syndrome.
Option E: Option E is incorrect because there is no evidence of thyroid dysfunction, and levothyroxine does not treat cytokine release syndrome.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. On day 6 after infusion, as his fever resolves, he becomes confused with expressive aphasia and an ICE (immune effector cell-associated encephalopathy) score of 4, without recurrent fever or hypotension, consistent with grade 3 ICANS. What is the most appropriate management?

A) Give tocilizumab as first-line therapy, exactly as for cytokine release syndrome.
B) Withhold all treatment because ICANS resolves spontaneously without intervention.
C) Start phenytoin as the preferred antiseizure agent and avoid all corticosteroids.
D) Start IV dexamethasone (for example, 20 mg every 6 hours), begin levetiracetam for seizure prophylaxis, arrange ICU-level monitoring, and do not give tocilizumab, which is ineffective for ICANS and may worsen it.
E) Increase the CAR-T cell dose to overcome the neurotoxicity.

ANSWER: D

Rationale:

ICANS responds to corticosteroids (dexamethasone), which cross into the central nervous system; tocilizumab is ineffective for ICANS and may worsen it because peripheral IL-6-receptor blockade can raise free IL-6 that crosses the blood-brain barrier. Grade 3 ICANS warrants IV dexamethasone, seizure prophylaxis with levetiracetam, and ICU-level monitoring.

Option A: Option A is incorrect because tocilizumab is first-line for cytokine release syndrome, not ICANS.
Option B: Option B is incorrect because grade 3 ICANS is dangerous and requires prompt treatment.
Option C: Option C is incorrect because levetiracetam (not phenytoin) is preferred and corticosteroids are the mainstay rather than something to avoid.
Option E: Option E is incorrect and dangerous because raising the CAR-T dose would intensify the immune-mediated injury.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. As he recovers and prepares for discharge, the team reviews the post-CAR-T safety requirements mandated under the risk evaluation and mitigation strategy (REMS) program. Which set of requirements is correct?

A) He may be treated at any facility, drive immediately, and needs no special documentation after infusion.
B) Monitoring at the treatment center for 24 hours is sufficient, and tocilizumab need not be available on site.
C) He should avoid live and inactivated vaccines permanently and requires no neurology availability.
D) The only requirement is monthly outpatient laboratory testing with no driving or activity restrictions.
E) CAR-T must be given at a REMS-certified center with tocilizumab and ICU capability available; he must be monitored at the treatment center for at least 7 days, must not drive or operate heavy machinery for at least 8 weeks because of ICANS risk, and should carry a patient card to alert providers, as late cytokine release syndrome and ICANS have been reported.

ANSWER: E

Rationale:

CAR-T products are administered under a REMS program: only certified centers with immediate access to tocilizumab and on-site ICU capability may dispense them; patients are monitored at the treatment center for at least 7 days, must not drive or operate heavy machinery for at least 8 weeks because of ICANS risk, and should carry a patient card because late cytokine release syndrome and ICANS have been reported weeks after infusion.

Option A: Option A is incorrect because treatment is restricted to certified centers, with driving and documentation requirements.
Option B: Option B is incorrect because monitoring is for at least 7 days and tocilizumab must be available on site.
Option C: Option C is incorrect because inactivated vaccines are not permanently prohibited (live vaccines are avoided during therapy) and neurology availability is part of certification.
Option D: Option D is incorrect because there are explicit driving and activity restrictions beyond laboratory monitoring.

21. [CASE 6 — QUESTION 1] A 60-year-old woman has a well-differentiated metastatic midgut neuroendocrine tumor (a tumor arising from hormone-producing cells) causing carcinoid syndrome with flushing and diarrhea. Her oncologist plans to start a somatostatin analog (a drug that mimics the body's hormone somatostatin). What is the principal therapeutic rationale for this class in her disease?

A) Somatostatin analogs cure neuroendocrine tumors by directly delivering a cytotoxic payload to tumor DNA.
B) Somatostatin analogs bind somatostatin receptors (especially SSTR2) on the tumor to suppress secretion of the hormones driving carcinoid symptoms (flushing and diarrhea) and also provide an antiproliferative effect in well-differentiated neuroendocrine tumors.
C) Somatostatin analogs stimulate hormone secretion from the tumor to exhaust its reserves.
D) Somatostatin analogs act by blocking the androgen receptor, identical to prostate cancer therapy.
E) Somatostatin analogs work only by lowering blood glucose and have no effect on carcinoid symptoms.

ANSWER: B

Rationale:

Somatostatin analogs bind somatostatin receptors (particularly SSTR2) on neuroendocrine tumor cells, suppressing secretion of the hormones that cause carcinoid symptoms such as flushing and diarrhea, and they provide antiproliferative benefit in well-differentiated tumors.

Option A: Option A is incorrect because these agents act on receptors to suppress secretion and growth, not by delivering a cytotoxic payload to DNA.
Option C: Option C is incorrect because they suppress, rather than stimulate, hormone secretion.
Option D: Option D is incorrect because they act on somatostatin receptors, not the androgen receptor.
Option E: Option E is incorrect because their primary benefit is controlling carcinoid symptoms and tumor growth; effects on glucose are a separate consideration that varies by agent.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. She is started on octreotide and the team weighs it against pasireotide, which has broader somatostatin-receptor affinity including SSTR5. Integrating the receptor profiles with their characteristic adverse effects, which statement best guides monitoring and selection?

A) Pasireotide causes less hyperglycemia than octreotide because its broader receptor binding protects insulin secretion.
B) Octreotide and pasireotide are pharmacologically identical, so monitoring is the same and selection is arbitrary.
C) Octreotide's main long-term risk is profound bone loss requiring DEXA monitoring, while pasireotide has no metabolic effects.
D) Long-term octreotide or lanreotide reduces gallbladder motility and promotes biliary sludge and gallstones (warranting periodic abdominal ultrasound), whereas pasireotide's broader SSTR5 activity markedly increases hyperglycemia by suppressing insulin secretion (warranting intensified glucose monitoring), so octreotide or lanreotide is generally preferred for routine secretory control unless the broader profile is specifically needed.
E) Both agents primarily cause acute bone marrow suppression and require weekly blood counts.

ANSWER: D

Rationale:

Octreotide and lanreotide reduce gallbladder motility, promoting biliary sludge and gallstones over time, so periodic abdominal ultrasound is recommended; pasireotide's broader receptor activity (notably SSTR5) strongly suppresses insulin secretion and causes substantially more hyperglycemia, warranting intensified glucose monitoring. Octreotide or lanreotide is generally preferred for routine secretory control unless the broader profile is needed.

Option A: Option A is incorrect because pasireotide causes more, not less, hyperglycemia.
Option B: Option B is incorrect because the agents differ in receptor affinity, adverse effects, and monitoring.
Option C: Option C is incorrect because the characteristic octreotide risk is biliary sludge and gallstones, not profound bone loss, and pasireotide clearly has metabolic (glucose) effects.
Option E: Option E is incorrect because these agents do not characteristically cause acute marrow suppression.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. Despite somatostatin analog therapy, her well-differentiated, somatostatin-receptor-positive neuroendocrine tumor progresses. The team considers peptide receptor radionuclide therapy (PRRT) with lutetium-177 dotatate (Lutathera). What is the mechanistic basis for this treatment?

A) It links a radioactive isotope (lutetium-177) to a somatostatin analog peptide so the radiopharmaceutical binds somatostatin receptors on the tumor and delivers targeted radiation to receptor-expressing tumor cells.
B) It is an oral androgen-receptor blocker that starves the tumor of testosterone.
C) It is a checkpoint inhibitor that releases the brakes on T cells against the tumor.
D) It is a selective estrogen receptor degrader used for ESR1-mutant disease.
E) It is a cytotoxic alkylating agent given intravenously without any tumor targeting.

ANSWER: A

Rationale:

Peptide receptor radionuclide therapy couples a radioactive isotope (lutetium-177) to a somatostatin analog peptide; the construct binds somatostatin receptors on the tumor and delivers targeted radiation to receptor-expressing tumor cells, which is why it is used for somatostatin-receptor-positive progressive neuroendocrine tumors.

Option B: Option B is incorrect because it is not an androgen-receptor blocker; that is prostate cancer therapy.
Option C: Option C is incorrect because it is a targeted radiopharmaceutical, not a checkpoint inhibitor.
Option D: Option D is incorrect because it is not a selective estrogen receptor degrader; that class is used in breast cancer.
Option E: Option E is incorrect because the defining feature is receptor-targeted delivery of radiation, not untargeted cytotoxic alkylation.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. She is also a renal transplant recipient on maintenance immunosuppression. A separate aggressive malignancy is later diagnosed for which a PD-1 inhibitor would ordinarily be considered. Integrating how PD-1/PD-L1 blockade works with the biology of a transplanted organ, what is the principal concern?

A) There is no special concern, because checkpoint inhibitors act only on tumor cells and spare transplanted organs.
B) The main risk is predictable bone marrow suppression identical to cytotoxic chemotherapy, and the graft is not at risk.
C) The transplant guarantees that the tumor will respond, so checkpoint blockade can be given without monitoring.
D) Maintenance immunosuppression will completely prevent any checkpoint inhibitor activity, so the dose should simply be doubled.
E) Releasing the PD-1/PD-L1 brake can reactivate alloreactive T cells against the graft, carrying a high risk of acute allograft rejection (reported around 40% in renal transplant case series), so the decision requires explicitly weighing tumor benefit against graft loss.

ANSWER: E

Rationale:

PD-1/PD-L1 signaling helps maintain peripheral tolerance, including tolerance to a transplanted organ; blocking that axis can reactivate alloreactive T cells and precipitate acute graft rejection — reported at roughly 40% in renal allograft case series — so checkpoint blockade in a transplant recipient demands an explicit risk-benefit discussion balancing tumor control against losing the graft.

Option A: Option A is incorrect because checkpoint inhibitors act broadly on T-cell tolerance, not solely on tumor cells.
Option B: Option B is incorrect because the toxicity is immune-mediated graft rejection, not predictable cytotoxic myelosuppression.
Option C: Option C is incorrect because a transplant does not ensure tumor response and intensive monitoring is required.
Option D: Option D is incorrect because the problem is graft-directed immune reactivation, and doubling the dose would increase rejection risk rather than overcoming suppression.